CMC Biologics Announces Agreement With Daiichi Sankyo Company to Develop and Manufacture Antibodies

SEATTLE and COPENHAGEN, Denmark, October 26, 2011 /PRNewswire/ --

CMC Biologics today announced the execution of an agreement with Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. The two companies have recently begun work on their first joint project at CMC Biologics' Bothell manufacturing facility. Specific terms of the agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

"CMC Biologics is delighted to partner with Daiichi Sankyo, a leader among pharmaceutical companies worldwide with a heritage of scientific discovery that spans more than one hundred years," noted Gustavo F. Mahler, Ph.D., Global Chief Operations Officer at CMC Biologics. "We will be working closely with Daiichi Sankyo on the development and production of antibodies over the next several years."

Junichi Koga, Ph.D., Vice President, Biopharmaceutical Technology Research Laboratories at Daiichi Sankyo, commented, "I believe CMC Biologics is the best partner for Daiichi Sankyo because of their depth of experience and excellent quality. Together we have created a responsive working relationship to bring best-in-class biologics to patients in need."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit http://www.daiichisankyo.com.

About CMC Biologics

CMC Biologics (http://www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.